Why the study?
Does atorvastatin reduce miR-221/222 expression and increase endothelial progenitor cell numbers in patients with stable CAD compared to pravastatin?
Population
44 patients with stable CAD and 22 subjects without CAD (non-CAD)
Comparison
Atorvastatin 10 mg daily for 12 months vs Pravastatin 10 mg daily for 12 months
Design
RCT, randomized
Follow-up
12 months
Loading...
Atorvastatin may confer endothelial benefits over pravastatin in stable CAD; extends evidence for statin-specific pleiotropic effects on EPC and miR-221/222.
Does atorvastatin reduce miR-221/222 expression and increase endothelial progenitor cell numbers in patients with stable CAD compared to pravastatin?
Atorvastatin, but not pravastatin, decreases miR-221/222 levels and increases endothelial progenitor cell numbers in patients with stable CAD, suggesting a specific pleiotropic mechanism for its vascular benefits.
A 2009 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: